What Agispor Treats: Main Uses and Benefits

Agispor is commonly used to help with the management of a broad range of superficial fungal infections, which are conditions presenting with systemic or localized discomfort. The formulation is relevant when supportive symptom management is appropriate, especially in conditions where structural integrity is affected.

The medication is commonly used to help with conditions such as athlete’s foot (Tinea pedis), ringworm (Tinea corporis), and jock itch (Tinea cruris). It is applied in situations involving certain distressing symptoms, including pronounced redness (erythema) and persistent itching (pruritus), which are symptoms related to inflammatory or irritative states. The dual-action approach is particularly relevant for easing challenging symptoms in infections complicated by tissue hardening, notably onychomycosis (fungal infection of the nail).

Quick Fact: Support for Persistent Symptoms

The formulation supports management of infections where functional stability becomes affected, assisting with symptoms like scaling and inflammation, and contributing to better day-to-day comfort.

Regulatory References

1. Ministry of Health (Israel) Prescribing Information

Who can and cannot use Agispor?

Regulatory documents define specific populations who are eligible, restricted, or prohibited from using Agispor (a topical preparation containing Bifonazole and Carbamide Peroxide).

Eligibility Status	Officially Documented Restriction
Contraindicated (Must Not Use)	Individuals with a known hypersensitivity to the active substance Bifonazole or to any of the product’s excipients.
Contraindicated (Specific Use)	Treatment of nappy rash in infants is explicitly prohibited.
Restricted (Age-Related)	Use in infants and young children is not recommended except when conducted under medical supervision.
Restricted (Pregnancy)	Use is preferably avoided during the first trimester of pregnancy; use in the second and third trimesters requires a doctor’s careful benefit/risk assessment.
Restricted (Lactation)	Breastfeeding should be discontinued during treatment due to the unknown risk to the infant. The product should not be applied to the chest area.
Conditional Use (Allergies)	Patients with a history of sensitivity to other imidazole antifungal agents (such as clotrimazole) must use the product with caution.

The official label does not document any specific restrictions for use based on hepatic or renal impairment for the topical form. These classifications define who is permitted to use the medicine under standard conditions and who is either absolutely prohibited or requires mandatory medical oversight.

Interactions with other medicines and products

The official regulatory data for this topical medicine outlines a specific interaction concern, despite the drug’s low systemic absorption. No contraindications or timing-based separation requirements are documented.

---

Interaction scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Coumarin Anticoagulants (Antithrombotic Agents)
Specific interacting medicines (if explicitly listed)	Warfarin
Mechanistic basis of interactions	Pharmacokinetic interaction leading to altered exposure. The specific enzymatic pathway is not explicitly stated in the topical product’s label.
Timing-based interaction rules (if applicable)	None documented.
Population-specific interaction notes (if applicable)	None documented.
Interaction-related restrictions	Mandatory Monitoring Procedure of INR.

---

Interaction classifications (high-level)

Classification	Official Regulatory Information
Interaction severity classification	Classified as requiring Caution and Monitoring
Interaction-context constraints	The anticoagulant effect must be monitored

---

Resulting interaction structure

Official interaction statements:

• Co-administration of the active ingredient Bifonazole may lead to a measurable increase in the International Normalized Ratio (INR) when used concurrently with Coumarin Anticoagulants, such as Warfarin.
• Regulatory guidelines mandate that patients receiving anticoagulant therapy must have their INR closely monitored when this topical medicine is initiated or discontinued.
• No other medicinal products, food, alcohol, or supplements have documented interaction patterns that require restrictions in the official labeling.

Connection to the overall interaction profile (3 sentences): Regulatory documents define the product’s interaction structure by highlighting one primary pharmacokinetic-based concern involving increased exposure of Coumarin Anticoagulants. This concern establishes a mandatory procedural constraint for prescribers to closely monitor the patient's INR during co-administration. The documented interaction structure reflects a localized medicine with minimal, but critical, potential for systemic impact on narrow-therapeutic-index drugs.

Dual Inhibition of Fungal Cell Membrane Synthesis

The mechanism describes how the primary antifungal agent, Bifonazole, exerts its action by disrupting the fungal cell's critical infrastructure. Bifonazole inhibits two separate enzymes—Lanosterol 14alpha-demethylase and HMG-CoA reductase—in the ergosterol biosynthesis pathway . This dual blockade starves the fungal cell of ergosterol, the key stabilizing component of its membrane, while simultaneously causing the build-up of toxic sterol byproducts. The resulting molecular cascade compromises the cell membrane integrity, leading to the compromise of fungal cell structure and function.

---

Chemical Keratolysis for Enhanced Penetration

The mechanism of the second component, Carbamide Peroxide, is to increase the permeation rate into the affected tissue. Carbamide Peroxide acts as a keratolytic agent, chemically breaking down and softening the dense protein structure of keratin found in the host's pathologically thickened tissue. This action physically compromises the primary protective barrier of the affected tissue, allowing the antifungal agent to penetrate to fungicidal concentrations. This synergy results in an increased local concentration of the antifungal agent by reducing the physical barrier imposed by the pathological tissue.

How to Use Agispor: Official Administration Guidelines

Agispor is a topical medicine administered directly to the skin, nails, or scalp. The route is strictly external, and the application method for most forms (cream, solution, or gel) requires applying a small quantity, such as a 1/2 cm strip of cream or a few drops of solution, which is then gently massaged into the affected skin area. The standard regimen for most cutaneous mycoses mandates application once daily, typically scheduled for the evening or at bedtime to facilitate proper contact.

The overall use of the medicine is structured as a defined, time-bound course. Treatment duration is condition-specific: athlete's foot (Tinea pedum) requires a course of three consecutive weeks, while other conditions such as Pityriasis versicolor may require two weeks. For mycotic infections of the scalp, the shampoo formulation utilizes an intermittent schedule of three times per week over a total course of six consecutive weeks.

The Bifonazole/Carbamide Peroxide nail ointment involves a unique procedural structure for use against onychomycosis. The preparation is applied daily, and the treated nail must then be covered with an occlusive dressing (plaster) for 24 hours. Following this, the nail requires a 10-minute bath before the softened, infected parts are gently removed. Furthermore, medical guidance specifies that use in infants and toddlers must occur only under medical supervision.

Research Evidence / Overview of Studies for Agispor

---

Evidence for Use in Fungal Nail Infections (Onychomycosis)

Research exploring Agispor's components for fungal nail infections was studied for a specialized approach that uses the keratolytic component (Carbamide Peroxide) to first soften and help remove the infected part of the nail, followed by the application of the antifungal cream (Bifonazole). Studies exploring this two-stage process have been evaluated in various Randomized Controlled Trials (RCTs) and summarized in systematic reviews. These trials primarily monitored the criteria for a composite cure endpoint, which was measured by assessing criteria for mycological success (the absence of the fungus in laboratory tests) and clinical success (the visual appearance of the nail). The populations studied typically included adults with mild-to-moderate toenail infections.

The reports derived from these studies describe patterns observed in the treatment setting, including the rate at which changes in the targeted nail tissue were observed by the keratolytic component. Research highlights changes measured during the study period related to the outcomes related to fungal status and the subsequent changes in the nail bed's condition. The regulatory evidence for this specific two-stage protocol is generally characterized as High.

Evidence for Use in Dermatophytoses of the Skin

For common skin fungal conditions like athlete’s foot (Tinea pedis) and ringworm (Tinea corporis), the evidence base has primarily involved clinical trials focusing on the antifungal ingredient, Bifonazole, often comparing it to other topical antifungals. These studies research examined outcomes such as Mycological Cure and the Clinical Resolution of visible signs of infection, like redness and scaling. The existing body of research for the dual-action formulation specifically in superficial skin infections is characterized as Moderate.

---

Understanding Long-Term Outcomes and Durability of Results

Studies exploring Agispor's components have monitored outcomes over defined time intervals, but there is variation in the duration of follow-up reported across the literature. Follow-up durations were limited in many of the core studies, which means research provides context but not individual predictions of long-term results. Data for the durability of the reported outcomes—meaning how often the infection was observed to relapse after the study intervention ended—are not consistently well-characterized across all major publications.

Research Gaps and Areas of Uncertainty

Research Limitation Frames note that results apply only to the populations studied, and findings were mixed in some instances at later follow-up points. Comparative evidence is lacking for certain specific clinical scenarios, and overall, evidence quality varies across studies.

Key Studies & References

1. Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin
2. Health Products Regulatory Authority (HPRA) Public Assessment Report for Bifonazole 1% Cream (Regulatory review of quality and non-clinical data)
3. Onychomycosis: Old and New (Review defining endpoints and recurrence rates)

Common questions about Agispor (FAQ)

Q: Is Agispor a kind of antibiotic?

A: According to official sources, the active ingredient Bifonazole is classified as an azole antifungal medicine. This means its mechanism is focused on treating fungal infections. The medicine is not classified as an antibiotic.

---

Q: What is the main difference between Agispor and other medicines for the same condition?

A: Official product information describes that the primary antifungal component, Bifonazole, has a unique dual mechanism of action. This means it is described as targeting two separate steps in the fungal cell’s process for building its protective membrane. This dual action is a point of distinction from some other antifungals.

---

Q: Can older adults (seniors) use Agispor?

A: Official regulatory documents do not specify any age-related restrictions or mandatory adjustments for the topical formulation when used by the elderly population. The focus of special restrictions is generally on infants and pregnant or breastfeeding individuals.

---

Q: Is Agispor a steroid?

A: No, Agispor is not classified as a steroid. The medicine is described in official sources as containing two active ingredients: an imidazole antifungal (Bifonazole) and a keratolytic agent (Carbamide Peroxide). These components work to eliminate the fungus and soften affected tissue.

---

Q: Does Agispor treat the root cause, or just the symptoms?

A: Regulatory information describes the medicine’s mechanism of action as compromising the structure and function of the fungal cells themselves. Regulatory information describes that this action is designed to target the fungal pathogen, which is considered the underlying cause of the infection.

---

Q: Does Agispor have any long-term effects that people worry about?

A: Studies and official information indicate that follow-up periods in the core clinical trials for this product were often limited. This means that data concerning the durability of the reported outcomes—or how often the infection was observed to return—are not consistently well-characterized across all major publications.

---

Q: What should I do if a minor side effect of Agispor is bothering me?

A: Official patient leaflets often state that if localized side effects become intolerable or cause significant discomfort, cessation of treatment may be indicated. Regulatory guidance advises that a healthcare professional be consulted as soon soon as possible if effects are bothersome or severe.

---

Q: Are there any required tests before starting Agispor?

A: Regulatory guidelines describe a specific mandatory monitoring procedure for a narrow group of patients. For individuals concurrently using Coumarin Anticoagulants, such as Warfarin, official guidance requires close monitoring of the International Normalized Ratio (INR) when the topical medicine is started or stopped.

---

Q: Is Agispor available over the counter, or is it prescription only?

A: The legal classification of Agispor is subject to local regulatory scheduling. In many regions, this product is restricted and may be classified as 'Prescription Only' or potentially available only under the supervision of a pharmacist. Information regarding the product's precise access status is available from local regulatory authorities or a pharmacist.

---

Q: Does Agispor affect my ability to drive or operate machinery?

A: Official regulatory documents state that the medicine is not expected to affect the ability to drive or operate machinery. This is because the product is designed for topical use and has a very low rate of systemic absorption into the bloodstream.

---

Q: Is Agispor considered a drug with high potential for abuse or dependence?

A: Official classification documents indicate that the active ingredients of Agispor are not listed under controlled substance schedules. This means the product is not classified by regulatory bodies as a substance with potential for abuse or dependence.

---

Q: What is the half-life of Agispor?

A: Official regulatory documents state that the systemic absorption of the antifungal component (Bifonazole) after topical application is very low, described as approximately 0.6% of the applied dose. Because the medicine is designed to act locally on the skin or nail, specific systemic pharmacokinetic data, such as half-life, are generally not the key focus of the product information.

How to Store and Dispose of Agispor

Official regulatory guidelines strictly define the conditions required for storing and disposing of Agispor (Bifonazole/Carbamide Peroxide) to maintain its stability and ensure environmental safety.

Storage Requirements

Condition	Requirement
Environment	Store the medicine in a cool dry place.
Protection	The product must be protected from direct sunlight.
Packaging	Keep the medicine stored in its original container/carton.
Child Safety	The product must be kept out of sight and reach of children.
Stability	Use the product only up to the Expiry date shown on the label.

Disposal Instructions

Medicines should not be disposed of via wastewater or household waste. To ensure proper disposal, consult your pharmacist for guidance on how to safely discard any unused or expired Agispor product, following local regulations for pharmaceutical waste.